ストックスクリーナーアプリを入手
34.22
0.54%
-0.2712
前日終値:
$34.49
開ける：
$34.69
24時間の取引高:
254.63K
Relative Volume:
0.47
時価総額：
$1.59B
収益：
-
当期純損益:
$-166.31M
株価収益率:
-7.672
EPS:
-4.4602
ネットキャッシュフロー:
$-160.59M
1週間 パフォーマンス:
-1.26%
1か月 パフォーマンス:
+13.03%
6か月 パフォーマンス:
+74.66%
1年 パフォーマンス:
+70.07%
1日の値動き範囲:
$34.05
$35.15
1週間の範囲:
$33.99
$35.60
52週間の値動き範囲:
$16.10
$35.83
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Compare AVBP vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
34.17 | 1.61B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.94 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.97 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-12-10 | 開始されました | BTIG Research | Buy |
| 2025-11-25 | 開始されました | Truist | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-03-20 | 開始されました | B. Riley Securities | Buy |
| 2025-03-10 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
すべてを表示
Arrivent Biopharma Inc (AVBP) 最新ニュース
ArriVent’s Emerging CDH17-Targeted ADC Pipeline Supports Maintained Buy Rating and $45 Price Target - TipRanks
ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings - TradingView
Price-Driven Insight from (AVBP) for Rule-Based Strategy - Stock Traders Daily
Number of shareholders of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Number of shareholders of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
Price to book forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Enterprise value to revenue forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Price to book forward of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
Price to earnings forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Price to earnings forward of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
Price to sales forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
AVBP 260717 5.00P (AVBP260717P5000) Stock Options Chain | Quotes & News - Moomoo
ArriVent BioPharma, Inc. Actuals & Estimates (NASDAQ:AVBP) - TradingView
AVBP Forecast — Price Target — Prediction for 2027 - TradingView
Arrivent Biopharma Inc (AVBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 4 Arrivent Biopharma Inc For: 22 June By Investing.com - Investing.com India
ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options - Stock Titan
ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options at $31.74 - Stock Titan
ArriVent BioPharma Stockholders Back Board and Auditor Slate - TipRanks
ArriVent BioPharma (NASDAQ: AVBP) 2026 meeting backs board, auditor - Stock Titan
Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD - Investing.com UK
Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD By Investing.com - Investing.com South Africa
Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $31.74 - Moomoo
(AVBP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arrivent Biopharma Inc (AVBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arrivent Biopharma Inc (AVBP) Institutional Confidence - TradingKey
Arrivent Biopharma Inc (AVBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arrivent Biopharma Inc (AVBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arrivent Biopharma Inc (AVBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVBP: Directors were elected through 2029 and the auditor's appointment was ratified with strong support - TradingView
Arrivent Biopharma Inc (AVBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arrivent Biopharma Inc (AVBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arrivent Biopharma Inc (AVBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ArriVent BioPharma (AVBP) Stock Valuation After Growing Expectations For EGFR Firmonertinib Trials - Sahm
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
AVBP Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D InvestmentsTangible Book Value - newsline.com
AVBP Q1 2026 Earnings: EPS Miss Slightly Wider Than Forecast as Pre-Revenue Biotech Advances PipelineFinancial Data - dars.gov.et
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
(AVBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
AVBP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP) and Medtronic (MDT) - The Globe and Mail
ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors - TipRanks
Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight on ArriVent BioPharma stock By Investing.com - Investing.com Canada
Why Is ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Down Today? - Meyka
Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data - TipRanks
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $50 - Moomoo
AVBP Q1 2026 Earnings: EPS Misses Estimates as Stock Surges 11% on Pipeline OptimismShare Dilution Risk - The Legal Advocate
ArriVent BioPharma Price Target Raised to $45.00/Share From $43.00 by Truist Securities - Moomoo
ArriVent Biopharma assumed with a Buy at Truist - TipRanks
Truist Financial Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45 - Moomoo
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
Arrivent Biopharma Inc (AVBP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer |
Jul 11 '25 |
Option Exercise |
2.28 |
11,153 |
25,429 |
135,736 |
1.21%
3.14%
大文字化:
|
ボリューム (24 時間):